In a propensity-matched cohort of patients with heart failure with preserved ejection fraction (HFPEF), Dr Lund and colleagues reported that the use of renin-angiotensin system (RAS) antagonists (angiotensin-converting enzyme [ACE] inhibitors or angiotensin II receptor blockers) was associated with lower all-cause mortality.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados